<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02473939</url>
  </required_header>
  <id_info>
    <org_study_id>VR942/1/001</org_study_id>
    <nct_id>NCT02473939</nct_id>
  </id_info>
  <brief_title>An Evaluation of VR942 in Healthy Volunteers and Patients With Mild Asthma</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of VR942 in Healthy Subjects and Repeated Doses in Mild Asthmatics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vectura Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vectura Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to Evaluate the safety, tolerability, pharmacodynamics and&#xD;
      pharmacokinetics of single inhaled doses of VR942 in healthy subjects (part 1) and repeated&#xD;
      doses in mild asthmatics (part 2).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of the safety and tolerability of single doses of VR942 in healthy subjects and repeated doses of VR942 in mild asthmatics</measure>
    <time_frame>28 days</time_frame>
    <description>o Vital signs, physical examinations, any AEs or adverse device effects, laboratory tests, spirometry, and ECG variables</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The pharmacodynamics of repeat doses of VR942 in mild asthmatics</measure>
    <time_frame>28 days</time_frame>
    <description>o Change in biomarker levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pharmacokinetic profile of single (Part 1) and repeated doses (part 2) of VR942 (time frame 4 and 14 days for Part 1 &amp; 2 respectively):</measure>
    <time_frame>4 and 14 days for Part 1 and 2 respectively</time_frame>
    <description>Part 1:&#xD;
Cmax, tmax, t½, AUC0-t, AUC0-∞ and Kel&#xD;
Part 2:&#xD;
Cmax, tmax, and AUC0-τ (post-dose on Day 1) Ctrough on Days 2, 9 and 10 Cmax, tmax, t½, AUC0-t, AUC0-τ, Kel (post-dose on Day 10) Accumulation ratio Racc (Cmax on Day 10/Cmax on Day 1), (AUC0-τ on Day 10/AUC0-τ on Day 1) and (Cmin on Day 10/Cmin on Day 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of used blisters and inhalers that do not meet the performance characteristics of the device intended by the manufacturer</measure>
    <time_frame>28 days</time_frame>
    <description>o Examination of a sample of used blisters and inhalers will be conducted</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>VR942 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VR942 Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VR942 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VR942 Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VR942 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VR942 Dose 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VR942 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VR942 Dose 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VR942 Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VR942 Dose 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VR942 delivered via a Vectura Dry Powder Inhaler</intervention_name>
    <arm_group_label>VR942 Dose 1</arm_group_label>
    <arm_group_label>VR942 Dose 2</arm_group_label>
    <arm_group_label>VR942 Dose 3</arm_group_label>
    <arm_group_label>VR942 Dose 4</arm_group_label>
    <arm_group_label>VR942 Dose 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo delivered via a Vectura Dry Powder Inhaler</intervention_name>
    <arm_group_label>VR942 Dose 1</arm_group_label>
    <arm_group_label>VR942 Dose 2</arm_group_label>
    <arm_group_label>VR942 Dose 3</arm_group_label>
    <arm_group_label>VR942 Dose 4</arm_group_label>
    <arm_group_label>VR942 Dose 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Part I &amp; 2:&#xD;
&#xD;
          -  Male or female subject.&#xD;
&#xD;
          -  Female subjects of non-childbearing potential&#xD;
&#xD;
          -  Weigh at least 50 kg, and body mass index 18.0-31.0&#xD;
&#xD;
          -  Peak inspiratory flow (PIF) of at least 60 L/min for at least 2 sec&#xD;
&#xD;
          -  Forced expiratory volume in 1 sec (FEV1)/forced vital capacity (FVC) ratio of at least&#xD;
             0.7 at the screening visit&#xD;
&#xD;
          -  Willingness to give written consent to participate after reading the information and&#xD;
             consent form&#xD;
&#xD;
          -  Willingness to give written consent to have data entered into The Over volunteering&#xD;
             Prevention System.&#xD;
&#xD;
          -  Additional inclusion criteria for Part 1:&#xD;
&#xD;
          -  Healthy subjects with FEV1 and FVC of at least 80% of the predicted value at the&#xD;
             screening visit&#xD;
&#xD;
          -  Additional inclusion criteria for Part 2:&#xD;
&#xD;
          -  Patients with documented clinical history of mild bronchial asthma (mild as defined by&#xD;
             the GINA guidelines1) for at least 6 months before the screening visit&#xD;
&#xD;
          -  Patient FEV1 and FVC of at least 70% of the predicted value at the screening visit&#xD;
&#xD;
        Exclusion Criteria for Part 1 &amp; 2:&#xD;
&#xD;
          -  Clinically relevant abnormal history, physical findings, ECG, or laboratory values at&#xD;
             the pre-trial screening assessment&#xD;
&#xD;
          -  Presence of acute or chronic illness or history of chronic illness sufficient to&#xD;
             invalidate the subject's participation in the trial or make it unnecessarily hazardous&#xD;
             (excluding mild asthma in Part 2)&#xD;
&#xD;
          -  Impaired endocrine, thyroid, hepatic, respiratory (excluding mild asthma in Part 2) or&#xD;
             renal function, diabetes mellitus, coronary heart disease, cancer, or history of any&#xD;
             psychotic mental illness&#xD;
&#xD;
          -  Respiratory tract infection within 4 weeks before the screening visit&#xD;
&#xD;
          -  History of surgery or medical intervention, or planned surgery or medical intervention&#xD;
&#xD;
          -  Presence or history of severe adverse reaction to any drug, or sensitivity to&#xD;
             components of the trial medication&#xD;
&#xD;
          -  Use of a prescription or over-the-counter medicine, with the exception of&#xD;
             acetaminophen (paracetamol), during the 7 days before the first dose of trial&#xD;
             medication. For Part 2 only, inhaled short-acting ß2 agonists, and ICS (stable dose&#xD;
             with at least 2 weeks documented use of ≥80% compliance before screening and Day -1)&#xD;
             are permitted&#xD;
&#xD;
          -  Participation in another clinical trial of a new chemical entity, new device, or a&#xD;
             prescription medicine within the 3 months before dosing, or participation within 5&#xD;
             half-lives of receiving an experimental drug (whichever is longer)&#xD;
&#xD;
          -  Presence or history of drug or alcohol abuse&#xD;
&#xD;
          -  Evidence of drug abuse on urine testing, or a positive test for alcohol&#xD;
&#xD;
          -  Current smoker; or ex-smokers who (a) gave up less than 1 year ago, or (b) who have a&#xD;
             history of more than 10 pack-years&#xD;
&#xD;
          -  Blood pressure and heart rate at the screening examination outside the ranges 90-140&#xD;
             mm Hg systolic, 40-90 mm Hg diastolic; heart rate 40-100 beats/min.&#xD;
&#xD;
          -  Loss of more than 400 mL blood, eg as a blood donor, or donation of blood products,&#xD;
             during the 3 months before the trial&#xD;
&#xD;
          -  Positive test for hepatitis B, hepatitis C, or HIV&#xD;
&#xD;
          -  Possibility that the subject will not cooperate with the requirements of the protocol,&#xD;
             including effective use of the DPI&#xD;
&#xD;
          -  Additional exclusion criteria for Part 2:&#xD;
&#xD;
          -  Life-threatening asthmatic episode in the past&#xD;
&#xD;
          -  Asthmatic episode or respiratory tract infection requiring steroid treatment in the&#xD;
             past 3 months&#xD;
&#xD;
          -  Use of the following medicines within the specified time before screening:&#xD;
&#xD;
               -  Long-acting ß2 agonists; At any time before screening&#xD;
&#xD;
               -  Anti IgE therapy; 6 months&#xD;
&#xD;
               -  Inhaled corticosteroids (&gt;500 µg per day of beclometasone dipropionate (BDP) or&#xD;
                  equivalent); 8 weeks&#xD;
&#xD;
               -  Oral or injectable steroids; 8 weeks&#xD;
&#xD;
               -  Intranasal or topical steroids; 4 weeks&#xD;
&#xD;
               -  Leukotriene antagonists; 2 weeks&#xD;
&#xD;
               -  Xanthines (excluding caffeine), anticholinergics, cromoglycates; 1 week&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vectura Study Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>May 29, 2015</study_first_submitted>
  <study_first_submitted_qc>June 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2015</study_first_posted>
  <last_update_submitted>December 19, 2016</last_update_submitted>
  <last_update_submitted_qc>December 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

